Cipla posted a net profit of Rs 1,492.44 crore for the 2018-19 fiscal as against Rs 1,416.57 crore in 2017-18.
The company said it’s planning to launch at least one limited competition drug every month.
The company board has approved raising up to Rs 6,000 crore
'We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations,' the company said in a BSE filing.
Cipla has taken support on a support line and the pitchfork. The stock can move higher from current level offering a good risk reward trade
Contra traders should look for short selling opportunity around 11,750/11,760 with a final stop loss at 11,810
Cipla's Ambrisentan tablets 5 mg and 10 mg is AB-rated generic therapeutic equivalent version of Gilead Sciences Inc's Letairis.
Dr Reddy's Laboratories Inc, a subsidiary of the Hyderabad-based Dr Reddy's Laboratories, is voluntarily recalling the affected lot of bottles on account of certain deviations from the Current Good Manufacturing Practice (CGMP) regulations.
Net Sales are expected to increase by 7.3 percent Y-o-Y (down 1 percent Q-o-Q) to Rs. 3,969.1 crore, according to Kotak.
Pulmazole an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, it added.
Net Sales are expected to increase by 9.5 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 3,829.1 crore, according to Prabhudas Lilladher.
Niveoli is used in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD), Cipla said in a BSE filing.
The top Nifty gainers include Cipla, Indiabulls Housing Finance, ONGC, Zee Entertainment and Kotak Mahindra Bank while TCS, Hindalco Industries, HCL Tech, Hero MotoCorp and HDFC are the top losers.
The top Nifty gainers include Tata Steel, Cipla, Eicher Motors, UltraTech Cement and Vedanta while State Bank of India, Power Grid, Britannia Industries, Tata Motors and Zee Entertainment are the top losers.
Pulmazole is an inhaled anti-fungal formulation of itraconazole aimed at treating allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.
These observations are both product specific and GMP observations related to the manufacturing and quality processes, Cipla said
The USFDA inspection covered 3 units at Kurkumbh plant.
Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk
The industry doyen pointed out that 70 percent of the major drugs are in-licensed and it is what India should look to do.
Cipla said, its cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg) is generic therapeutic equivalent version of Sensipar, a branded drug marketed by Amgen Inc.
Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors' clinics or co-packaging on select Cipla brands.
HDFC Securities is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 605 in its research report dated February 07, 2019.
ICICI Direct recommended hold rating on Cipla with a target price of Rs 545 in its research report dated February 07, 2019.